脑膜瘤的放射性配体治疗:证据与未来方向
脑膜瘤是成人最常见的颅内肿瘤,WHO 2级和3级复发风险高,局部治疗手段用尽后亟需新策略。放射性核素治疗将肿瘤特异性抗体或配体的靶向性与放射性核素的细胞毒性结合,整合分子影像可无创评估预测性生物标志物。「诊疗一体化」概念最初在甲状腺疾病、神经内分泌肿瘤和前列腺癌等颅外肿瘤中发展,回顾性病例系列和早期临床试验数据支持该策略在脑膜瘤中的潜力。本综述探讨脑膜瘤放射性核素治疗的现有证据和正在进行的临床试验,并讨论最佳临床试验设计和该领域的未来展望。
要点
- 脑膜瘤是成人最常见的颅内肿瘤,WHO 2级和3级常规治疗后复发风险仍高。
- 放射性核素治疗结合肿瘤特异性抗体或配体的靶向性与放射性核素的细胞毒性。
- 整合分子影像可无创评估作为治疗靶点的预测性生物标志物。
核心结论
- 回顾性病例系列和早期临床试验数据支持放射性核素治疗策略在脑膜瘤中的潜力。
研究设计与样本
- 综述,探讨脑膜瘤放射性核素治疗的现有证据和正在进行的临床试验,并讨论最佳临床试验设计和未来展望。
主要发现
- 「诊疗一体化」概念最初在甲状腺疾病、神经内分泌肿瘤和前列腺癌等颅外肿瘤中发展。
- 回顾性病例系列和早期临床试验数据支持该策略在脑膜瘤中的潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meningiomas are the most common intracranial neoplasms in adults. While most meningiomas are cured by resection, further treatment by radiotherapy may be needed, particularly in WHO grades 2 and 3 tumors which have an increased risk of recurrence, even after conventional therapies. Still, there is an urgent need for novel therapeutic strategies after the exhaustion of local treatment approaches. Radionuclide therapies combine the specificity of tumor-specific antibodies or ligands with the cytotoxic activity of radioactive emitters. Alongside this, integrated molecular imaging allows for a noninvasive assessment of predictive biomarkers as treatment targets. Whereas the concept of "theranostics" has initially evolved in extracranial tumors such as thyroid diseases, neuroendocrine tumors, and prostate cancer, data from retrospective case series and early phase trials underscore the potential of this strategy in meningioma. This review aims to explore the available evidence of radionuclide treatments and ongoing clinical trial initiatives in meningioma. Moreover, we discuss optimal clinical trial design and future perspectives in the field, including compound- and host-specific determinants of the efficacy of "theranostic" treatment approaches.
引用
- Mair MJ, Tabouret E, Johnson DR, et al. Radioligand therapies in meningioma: Evidence and future directions. Neuro Oncol. 2024. PMID: 38702966. doi:10.1093/neuonc/noae069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。